Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study

Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study

by , , | Aug 25, 2025 | Journal Club, Neurology, Pre-Hospital

Methodology: 4/5 Usefulness: 4/5 Christenson J, et al. Lancet. 2025 Feb 15;405(10478):571-582. doi: 10.1016/S0140-6736(25)00193-X.  Question and Methods: Double-blind, placebo-controlled RCT to determine if prehospital administration of nerinetide for suspected acute...
Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial

Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial

by , , | Jan 2, 2024 | Critical Care, Full Article, Journal Club, Neurology

Methodology: 4/5 Usefulness: 2/5 Liu L, et al. BMJ. 2023 Oct 9;383:e076448.  Question: Do early vs delayed blood pressure management in patients with mild-moderate acute ischemic strokes decrease death or dependency at 90 days? Methods: Randomization to early (24 hrs)...
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial

by , , | Sep 26, 2022 | Journal Club, Neurology

Methodology: 4.5/5 Usefulness: 5/5 Menon BK, et al. Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Question and Methods: This multicentre, open label, randomized control trial at 22 primary and comprehensive stroke centres across Canada...